Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADGI

Adagio Therapeutics (ADGI) Stock Price, News & Analysis

Adagio Therapeutics logo

About Adagio Therapeutics Stock (NASDAQ:ADGI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$3.40
$4.78
52-Week Range
N/A
Volume
22,357 shs
Average Volume
2.27 million shs
Market Capitalization
$504.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Receive ADGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADGI Stock News Headlines

Our Favorite Advent Calendars
Forget Guessing Earnings—Trade Smarter with the “12:05 Indicator”
Most people don’t know this… Out of the 500 stocks in the S&P 500… Stocks like Nvidia, Tesla, and Apple - the MAG7 - are the ones really moving the markets. Take a look at this chart of the 20 largest stocks causing 75% of the market volatility: These stocks are causing more than twice the average volatility. And that’s great to know if you love trading the markets as much as I do. It means you have fewer stocks to watch… But you’d better watch them close when they make a big move.
See More Headlines

ADGI Stock Analysis - Frequently Asked Questions

Adagio Therapeutics, Inc. (NASDAQ:ADGI) posted its earnings results on Sunday, November, 14th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.24.

Adagio Therapeutics (ADGI) raised $301 million in an initial public offering (IPO) on Friday, August 6th 2021. The company issued 17,700,000 shares at a price of $16.00-$18.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagio Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), PayPal (PYPL), Tesla (TSLA), AbbVie (ABBV) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/14/2021
Today
5/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADGI
Fax
N/A
Employees
2,021
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-226,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.02 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$504.98 million
Optionable
Not Optionable
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ADGI) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners